Abstract
Innate and adaptive immunity has been shown to be critically involved in the pathogenesis of atherosclerosis. In particular, immune suppression mediated by regulatory T cells (Tregs) or tolerogenic dendritic cells (DCs) serves as a vital mechanism for regulating pathogenic chronic inflammation in atherogensis, suggesting that promotion of endogenous regulatory immune responses could be a possible therapeutic approach to suppress atherosclerotic disease. In this review, we discuss the possible role of Tregs and tolerogenic DCs in the prevention of atherosclerosis and the promising strategies to prevent or cure atherosclerotic disease by modulating regulatory immune responses mediated by these suppressor cells.
Keywords: Atherosclerosis, immune system, inflammation, regulatory T cells, tolerogenic dendritic cells.
Current Pharmaceutical Design
Title:Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Volume: 21 Issue: 9
Author(s): Naoto Sasaki, Tomoya Yamashita, Kazuyuki Kasahara, Masafumi Takeda and Ken-ichi Hirata
Affiliation:
Keywords: Atherosclerosis, immune system, inflammation, regulatory T cells, tolerogenic dendritic cells.
Abstract: Innate and adaptive immunity has been shown to be critically involved in the pathogenesis of atherosclerosis. In particular, immune suppression mediated by regulatory T cells (Tregs) or tolerogenic dendritic cells (DCs) serves as a vital mechanism for regulating pathogenic chronic inflammation in atherogensis, suggesting that promotion of endogenous regulatory immune responses could be a possible therapeutic approach to suppress atherosclerotic disease. In this review, we discuss the possible role of Tregs and tolerogenic DCs in the prevention of atherosclerosis and the promising strategies to prevent or cure atherosclerotic disease by modulating regulatory immune responses mediated by these suppressor cells.
Export Options
About this article
Cite this article as:
Sasaki Naoto, Yamashita Tomoya, Kasahara Kazuyuki, Takeda Masafumi and Hirata Ken-ichi, Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013142518
DOI https://dx.doi.org/10.2174/1381612820666141013142518 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Status of Pharmacological Thrombolytic Therapy and Mechanical Thrombectomy for the Treatment of Acute Deep Venous Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry Targeted Metabolomics Reveals Hippurate as a Urinary Potential Marker for Diabetic Nephropathy
Current Metabolomics Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Mycophenolate Mofetil for the Treatment of Systemic Sclerosis
Letters in Drug Design & Discovery Amino Thiols, Detoxification and Oxidative Stress in Pre-Eclampsia and Other Disorders of Pregnancy
Current Pharmaceutical Design Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Editorial [Hot Topic: The Clinical Management and Treatment of Hypertension, Its Pathophysiology and the Clinical Use of Antihypertensive Drugs (Executive Editor: Gregory Y.H. Lip)]
Current Pharmaceutical Design Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma
Protein & Peptide Letters Severe Preeclampsia
Current Women`s Health Reviews Structural and Molecular Tear Film Changes in Glaucoma
Current Medicinal Chemistry SLS-catalyzed Multi-component One-pot Reactions for the Convenient Synthesis of Spiro[indoline-3,4’-pyrano [2,3-c]pyrazole] Derivatives
Current Organocatalysis Inflammation, Sleep, Obesity and Cardiovascular Disease.
Current Vascular Pharmacology Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Antioxidant Activity and Chemical Components as Potential Anticancer Agents in the Olive Leaf (Olea europaea L. cv Leccino.) Decoction
Anti-Cancer Agents in Medicinal Chemistry Effects of Gynura procumbens Leaf Extracts on Plasma Lipid Peroxidation and Total Antioxidant Status in CCl4-Treated Rats
The Natural Products Journal Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Editorial: The Different Facets of Diabetes, Dyslipidemia and Hypertension in Cardio-metabolic Diseases: Current Perspective and Future Developments
Current Pharmaceutical Design Foreword [ Current Vascular Pharmacology is 10 Years Old! ]
Current Vascular Pharmacology